Pfizer

HERO-TOGETHER: A Safety Surveillance Study of Post- Vaccination Events of Interest among People Vaccinated Against COVID-19

Posted on by Jodi Snare

Study Updated 03/28/2024

Study Design: Prospective Observational
PCORnet Infrastructure: Collaboration, Engagement, Single IRB
Principal Investigator: Emily O’Brien
Site Name: Duke Clinical Research Institute
PCORnet® Network Partner: Coordinating Center
Funder: Pfizer
Funding Date: 2020
Study Duration: 2020 – 2022
Participating Clinical Research Networks: GPC, INSIGHT, OneFlorida+, PaTH, REACHnet, STAR
Therapeutic Area: Infectious Disease
Status: Completed

Research Question(s): In this study, the research team wanted to learn if taking HCQ was safe and prevented COVID-19 in healthcare workers.

Outcomes Database to Prospectively Assess Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC)

Posted on by Jodi Snare

Study Updated 03/28/2024

ClinicalTrials.gov#: NCT04919122
Study Design: Prospective Observational
PCORnet Infrastructure: Collaboration, CDM (+supplemental data), Engagement
Principal Investigator: Dan George
Site Name: Duke Clinical Research Institute
PCORnet® Network Partner: Coordinating Center
Funder: Exelixis, Bristol Myers Squibb, Merck, Pfizer
Funding Date: 2020
Study Duration: 2022 – 2026
Participating Clinical Research Networks: GPC, PaTH, REACHnet, STAR
Therapeutic Area: Oncology
Condition: Metastatic Renal Cell Carcinoma
Population: 19 Years and older (Adult, Older Adult)
Status: Recruiting

Research Question(s):

Can a research registry of patients with metastatic renal cell carcinoma (mRCC) patients help us better understand cancer management and health-related quality of life while receiving mRCC specific treatment? In combination with patient and physician surveys, PCORnet will be used to help us answer these questions.

Estimating the Burden of Nonalcoholic Steatohepatitis Using a Multistate Electronic Health Record Data Network

Posted on by Jodi Snare

Study Updated 03/28/2024

Study Design: Retrospective Observational
PCORnet Infrastructure: Collaboration, CDM, Engagement
Principal Investigator: Kathleen McTigue
Site Name: University of Pittsburgh/UPMC
PCORnet® Network Partner: PaTH
Funder: Pfizer
Funding Date: 2020
Study Duration: 2020 – 2023
Participating Clinical Research Networks: OneFlorida+, PaTH, REACHnet
Therapeutic Area: Gastroenterology
Condition: Non-alcoholic Fatty Liver Disease (NAFLD)
Population:

Research Question(s):

  1. How do patients with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) compare with those who do not have these diagnoses?
  2. How is risk for liver fibrosis (calculated from 4 validated scores) distributed among patients with and without diagnoses for NASH or NAFLD?